The investigational Evident test requires 3 tumor markers on the same extracellular vesicle to flag early-stage ovarian cancer.
|Articles|August 2, 2011
HPV Testing and Cervical Cancer Screening: Questions Women Should Ask Their Doctor
Questions to help you begin the conversation about HPV and HPV testing with your doctor. These can help determine if HPV testing is right for you.
Advertisement
Below are some questions to help you begin the conversation about HPV and HPV testing with your doctor. These can help determine if HPV testing is right for you.
- -Do you provide HPV testing as part of management of abnormal Pap test results?
- -Are you familiar with the new American Cancer Society guidelines that offer a preliminary recommendation, pending FDA approval, that HPV DNA testing may be used in conjunction with the Pap test, to safely screen women age 30 and over for cervical cancer as frequently as every three years?
- -How do you screen your patients for cervical cancer?
- -When should I be screened next for cervical cancer?
- -Are you aware of the new Consensus Guidelines published in the Journal of the American Medical Association (in April 2002) that recommend HPV testing as the preferred approach for managing women with inconclusive Pap results, particularly when a liquid-based Pap test is initially used for screening?
- -If I have an inconclusive Pap test result, can you ask the laboratory to perform an automatic ("reflex") HPV test from the same Pap sample before calling me with the results?
- -Can I talk with you about additional questions I may have regarding HPV and cervical cancer?
Advertisement
Related to this article
Susan Reed, MD, on the need for menopause research funding, a clinical trials network, and studies in understudied groups and perimenopause.
Chrisandra Shufelt, MD, on why menopause is a window for cardiovascular prevention and the risk factors OB/GYNs should assess.
Matthew Nudy, MD, on estrogen's cardiovascular effects, risk assessment, and hormone therapy safety in younger menopausal women.
ACOG advises against GLP-1 receptor agonists in pregnancy and recommends considering discontinuation 1 to 2 months before conception.
Rhonda Voskuhl, MD, on a case series in which estriol and progesterone improved self-reported cognition in menopausal women at 12 months.
Joint guidance from the AHA, AAP, ACOG, and SMFM organizes cardiovascular prevention for girls and women around 4 female life stages.
In the premiere episode of Mind, Body, & the Pause, Soma Mandal, MD, is joined by Manisha Parulekar, MD, and Jocelyn Carlo, MD, FACOG, to discuss the stages of the menopause transition.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
ACOG advises against GLP-1 receptor agonists during pregnancy
2
Safety Monitoring and Dosing for NK3 Antagonists in Menopause VMS
3
Matthew Nudy, MD, on estrogen and the cardiovascular system
4
Susan Reed, MD, on the future of menopause research and funding
5